Evidence-Based Nursing of Patients with Hematologic Malignancies
Actual insides in the pathogenesis of hematologic malignancies have contributed to significant advances in the diagnosis and evolving treatment options for these diseases. This evolution warrants expanded and specialized knowledge and skills development for nurses to provide expert care to these patients. Understanding these new approaches needs, beyond basic training in hematology, a continuing education program for nurses as well as the development of critical thinking when reading scientific literature to provide evidence-based nursing interventions.
Expert and highly complex practice includes comprehensive assessment with validated tools, early recognition of a complication, prompt action, and care management (preventive and curative) in collaboration with the patient and other healthcare providers. Supportive care to improve the quality of life of our patients extends beyond symptom management and includes social, psychological, and spiritual care.
Nurses in hematology should also take the leadership in the development of new models of care such as nurse-led consultation, outpatient care, patient self-management, and survivorship care provision for the increasing number of hematology cancer survivors.
New and more general challenges to be faced by the hematology nurse are the occurrence of antimicrobial resistance, adherence to oral treatment, and effective and equal care to all patients in a context of multiculturality.
This chapter will highlight these recent advances and, there were possible, describe the evidence-based nursing interventions to assure high-quality physical and psychosocial care for hematologic patients.
Keywordsevidence-based nursing interventions specialized knowledge and skills comprehensive assessment validated tools early recognition leadership new models of care patient self-management innovative models of hematology survivorship care plans
- 1.Röllig C, Bornhäuser M, Thiede C, Taube F, Kramer M, Mohr B, Aulitzky W, Bodenstein H, Tischler HJ, Stuhlmann R, Schuler U, Stölzel F, von Bonin M, Wandt H, Schäfer-Eckart K, Schaich M, Ehninger G. Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European Leukemia Net recommendations: evaluation of the proposed reporting system. J Clin Oncol. 2011;29(20):2758–65. https://doi.org/10.1200/JCO.2010.32.8500.CrossRefPubMedGoogle Scholar
- 5.Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J, Gascoyne RD, Connors JM. The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109(5):1857–61. https://doi.org/10.1182/blood-2006-08-038257.CrossRefPubMedGoogle Scholar
- 9.Gutiérrez-García G, García-Herrera A, Cardesa T, Martínez A, Villamor N, Ghita G, Martínez-Trillos A, Colomo L, Setoain X, Rodríguez S, Giné E, Campo E, López-Guillermo A. Comparison of four prognostic scores in peripheral T-cell lymphoma. Ann Oncol. 2011;22(2):397–404. https://doi.org/10.1093/annonc/mdq359.CrossRefPubMedGoogle Scholar
- 10.National Comprehensive Network. NCCN clinical practice guidelines in oncology: non-hodgkin lymphoma. 2018. Retrieved from https://www.nccn.org/professionals/physician_gls/pdf/t-cell.pdf. Accessed 7 June 2018.
- 13.Evens AM, Gordon LI, Patton D, et al. Phase I results of combination gemcitabine and bortezomib (Velcade) for relapsed/refractory nodal T-cell non-Hodgkin lymphoma (T- NHL) and aggressive B-cell NHL (B-NHL). Blood. 2008;112(11). Abstract 2005.Google Scholar
- 16.Cavo M, Rajkumar SV, Palumbo A, Moreau P, Orlowski R, Bladé J, Sezer O, Ludwig H, Dimopoulos MA, Attal M, Sonneveld P, Boccadoro M, Anderson KC, Richardson PG, Bensinger W, Johnsen H, Kroeger N, Gahrton G, Bergsagel PL, Vesole DH, Einsele H, Jagannath S, Niesvizky R, Durie BG, Lonial S. International Myeloma Working Group (IMWG) consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem-cell transplantation. Blood. 2011; https://doi.org/10.1182/blood-2011-02-297325.CrossRefGoogle Scholar
- 17.Lokhorst H, Einsele H, Vesole D, Bruno B, San Miguel J, Pérez-Simon JA, Kröger N, Moreau P, Gahrton G, Gasparetto C, Giralt S, Bensinge W. International myeloma working group consensus statement regarding the current status of allogeneic stem- cell transplantation for multiple myeloma. J Clin Oncol. 2010;2829:4521–30.CrossRefGoogle Scholar
- 24.Cavaletti G, Frigeni B, Lanzani F, Piatti M, Rota S, Briani C, et al. The Total neuropathy score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute- common toxicity scale. J Peripher Nerv Syst. 2007;12:210–5.CrossRefGoogle Scholar
- 25.Tariman JD, Love G, McCullagh E, Sandifer S. IMF Nurse Leadership Board. Peripheral neuropathy associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board. Clin J Oncol Nurs. 2008;12(3 Suppl):29–36. https://doi.org/10.1188/08.CJON.S1.29-35.CrossRefPubMedPubMedCentralGoogle Scholar
- 26.Calhoun EA, Welshman EE, Chang CH, Lurain JR, Fishman DA, Hunt TL, Cella D. Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group—Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer. 2003;13:741–8. https://doi.org/10.1111/j.1525-1438.2003.13603.x.CrossRefPubMedGoogle Scholar
- 27.Cella DF FACIT: Functional Assessment of Cancer Therapy. 1997. Retrieved September 24, 2007, from http://www.facit.org/qview/qlist.aspx
- 30.Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, Chauhan C, Gavin P, Lavino A, Lustberg MB, Paice J, Schneider B, Smith ML, Smith T, Terstriep S, Wagner-Johnston N, Bak K, Loprinzi CL. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline summary. J Oncol Pract. 2014;106:e421–4.CrossRefGoogle Scholar
- 31.Smith EM, Pang H, Cirrincione C, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013;309:1359–67. https://doi.org/10.1001/jama.2013.2813.CrossRefPubMedPubMedCentralGoogle Scholar
- 33.National Cancer Institute. NCI dictionary of cancer terms: Myelosuppression. 2017. Retrieved from https://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=44173. Accessed 17 May 2018.
- 34.National Cancer Institute. Common terminology criteria for adverse events [v.4.03]. 2010. Retrieved from https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-0614_QuickReference_5x7.pdf. Accessed 20 May 2018.
- 35.Crighton GL, Estcourt LJ, Wood EM, Trivella M, Doree C, Stanworth S. A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation. Cochrane Database Syst Rev. 2015;9:CD010981.PubMedCentralGoogle Scholar
- 38.Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, et al. Recommendations of the Center for International Blood and Marrow Transplant Research (CIBMTR®), the National Marrow Donor Program (NMDP), the European Blood and Marrow Transplant Group (EBMT), the American Society of Blood and Marrow Transplantation (ASBMT), the Canadian Blood and Marrow Transplant Group (CBMTG), the Infectious Disease Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the Association of Medical Microbiology and Infectious Diseases Canada (AMMI), and the Centers for Disease Control and Prevention (CDC), guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Biology of blood and marrow transplantation. J Am Soc Blood Marrow Transplant. 2009;15(10):1143–238. https://doi.org/10.1016/j.bbmt.2009.06.019.CrossRefGoogle Scholar
- 41.Oncology Nursing Society. Prevention of infection: Transplant. 2017. Retrieved from https://www.ons.org/practice-resources/pep/prevention-infection/prevention-infection-transplant. Accessed 17 May 2018.
- 42.Kashiwazaki H, Matsushita T, Sugita J, Shigematsu A, Kasashi K, Yamazaki Y, et al. Professional oral health care reduces oral mucositis and febrile neutropenia in patients treated with allogeneic bone marrow transplantation. Support Care Cancer. 2012;20:367–73. https://doi.org/10.1007/s00520-011-1116-x.CrossRefPubMedGoogle Scholar
- 43.Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, Bekele BN, Raber-Durlacher J, Donnelly JP, Rubenstein EB. Mucositis Study Section of the Multinational Association for Supportive Care in Cancer; International Society for Oral Oncology. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer. 2004;100(9 Suppl):1995–2025.CrossRefGoogle Scholar
- 48.Miller AN, Glode A, Hogan KR, Schaub C, Kramer C, Stuart RK, Costa LJ. Efficacy and safety of ciprofloxacin for prophylaxis of polyomavirus BK virus-associated hemorrhagic cystitis in allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2011;17:1176–81. https://doi.org/10.1016/j.bbmt.2010.12.700.CrossRefPubMedGoogle Scholar
- 50.Mohty M, Malard F, Abecassis M, Aerts E, Alaskar AS, Aljurf M, et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2016;51(7):906–12. https://doi.org/10.1038/bmt.2016.130.CrossRefPubMedPubMedCentralGoogle Scholar